$54.99
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Updated COA's
Secure Shipping Guaranteed
Verified for Purity
$54.99
Research Chemical products are third-party tested by MZ Biolabs, an independent laboratory based in Arizona. Each batch is analyzed to ensure accuracy, purity, and that all specifications are met.
RU-58841 is a topical non-steroidal anti-androgen that has garnered significant attention in experimental dermatological research. Initially investigated for its ability to block dihydrotestosterone (DHT) at the receptor level, RU58841 is a potent androgen receptor antagonist used in models studying androgenic alopecia and related hair follicle responses.
RU-58841 selectively binds to androgen receptors in the skin, blocking the interaction with DHT, the androgen strongly associated with male pattern baldness and sebaceous gland activity. It does not significantly impact systemic testosterone levels or hormonal profiles in topical applications under controlled experimental settings.
RU-58841 has been explored in laboratory models for its potential to:
While RU58841 is not FDA-approved for medical or cosmetic use, its receptor-specific action has made it a compound of interest in androgen-related dermatological research.
1. Frizza, F., Maggi, M., & Lotti, F. (2023). Skin Androgen-Related Disorders: Hormonal Treatment. In European Handbook of Dermatological Treatments (pp. 1661-1678). Cham: Springer International Publishing.
2. Münster, U., NakamuraNachname, C., Haberland, A., Jores, K., Mehnert, W., Rummel, S., … & Schäfer-Korting, M. (2005). RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 60(1), 8-12.
3. De Brouwer, B., Tetelin, C., Leroy, T., Bonfils, A., & Van Neste, D. (1997). A controlled study of the effects of RU58841, a non‐steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone‐conditioned nude mice. British Journal of Dermatology, 137(5), 699-702.
4. Pan, H. J., Wilding, G., Uno, H., Inui, S., Goldsmith, L., Messing, E., & Chang, C. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 9, 39-43.
No. It is not a dietary or sports supplement and is not for human use.
No. RU58841 is not approved by the FDA and is intended strictly for research purposes.
Each dropper has measurements up to the 1ml line.
Each 30mL bottle contains RU58841 at a concentration of 50mg/mL.
RU58841 is a non-steroidal topical anti-androgen developed for research and is being studied for its effects on hair loss and androgen-mediated skin conditions.
Verified Purity: Third-party batch testing for quality assurance
Secure Packaging: UV-protected, leak-proof, and tamper-resistant bottles
Reliable Fulfillment: Fast, discreet shipping with tracked delivery
Supportive Team: Expert assistance for research-based questions
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
RU-58841 selectively binds to androgen receptors in the skin, blocking the interaction with DHT, the androgen strongly associated with male pattern baldness and sebaceous gland activity. It does not significantly impact systemic testosterone levels or hormonal profiles in topical applications under controlled experimental settings.
While RU58841 is not FDA-approved for medical or cosmetic use, its receptor-specific action has made it a compound of interest in androgen-related dermatological research.
1. Frizza, F., Maggi, M., & Lotti, F. (2023). Skin Androgen-Related Disorders: Hormonal Treatment. In European Handbook of Dermatological Treatments (pp. 1661-1678). Cham: Springer International Publishing.
2. Münster, U., NakamuraNachname, C., Haberland, A., Jores, K., Mehnert, W., Rummel, S., … & Schäfer-Korting, M. (2005). RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 60(1), 8-12.
3. De Brouwer, B., Tetelin, C., Leroy, T., Bonfils, A., & Van Neste, D. (1997). A controlled study of the effects of RU58841, a non‐steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone‐conditioned nude mice. British Journal of Dermatology, 137(5), 699-702.
4. Pan, H. J., Wilding, G., Uno, H., Inui, S., Goldsmith, L., Messing, E., & Chang, C. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 9, 39-43.
Join our insider list for the latest research insights, product releases, and special offers—delivered straight to your inbox.
